Artelo Biosciences, Inc. Transition report pursuant to Rule 13a-10 or 15d-10

Transition report pursuant to Rule 13a-10 or 15d-10

EQUITY (Detail Narrative)

EQUITY (Detail Narrative)							1 Months Ended			4 Months Ended		12 Months Ended
EQUITY (Detail Narrative)	Feb. 15, 2022 shares	Mar. 05, 2021 $ / shares shares	Feb. 12, 2021 $ / shares shares	Jun. 19, 2020 shares	Dec. 06, 2019 USD ($) $ / shares shares	Dec. 02, 2019 shares	Jul. 21, 2021 $ / shares shares	Nov. 30, 2020 $ / shares shares	Aug. 17, 2018 shares	Dec. 31, 2021 USD ($) integer $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Aug. 31, 2021 USD ($) $ / shares shares	Aug. 31, 2020 USD ($) $ / shares shares	Feb. 18, 2022 shares	Sep. 01, 2021 shares	Dec. 03, 2020 $ / shares shares	Oct. 14, 2020 shares	Oct. 10, 2020 shares	Jan. 01, 2020 $ / shares
Common stock, par value (in dollars per share) \| $ / shares										$ 0.001	$ 0.001		$ 0.001			$ 0.001
Common stock, shares authorized										750,000,000	750,000,000		750,000,000			18,750,000,000
Preferred stock, par value (in dollars per share) \| $ / shares										$ 0.001	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized										6,250,000	6,250,000	6,250,000	6,250,000
Preferred stock, shares outstanding										0	0	0	0
Preferred stock, shares issued										0	0	0	0
Common shares issued for settlement of debt \| $													$ 100,000
Number of purchase common stock shares \| integer										10,120,000
Common stock shares issued during period										17,774,310
Common stock, average price per share \| $ / shares										$ 1.06
Proceeds from commission and fees \| $										$ 18,262
Number of shares issued under options				425,000,000					375,000,000	748,738,000
Options exercisable description									Options may be exercisable (“vest”) immediately or in increments based on time and/or performance criteria as determined by the administrator. The term of any option may not exceed 10 years (five years for any incentive stock option granted to a 10% stockholder), and unless otherwise determined by the administrator, each option must terminate no later than three months after the termination of the optionee’s employment (one year in the event of death or disability). Subject to a few minor exceptions, options may not be transferred other than by will or by the laws of descent and distribution.
Number of warrant granted										10,120,000,000		10,120,000
Expiration date under plan									Aug. 17, 2028
Intrinsic value of the warrants \| $										$ 0		$ 338	$ 0
Number of shares granted during period										2,149,800,000		2,755,100	74,000,000
Common shares issued for cash \| $										$ 18,262,000	$ 6,578,000	$ 8,103,000	$ 1,978,000
Common stock, shares issued										42,301,013		24,526,703	4,991,587
Represents information of officer and director.
Common shares issued for cash (in shares)													45,834,000
Valuation [Member]
Options Granted										2,149,800		2,755,100	74,000
Option Granted, Value \| $										$ 1,170		$ 5,760	$ 190
Stock option expense \| $										934		1,497	336
Stock option expense, Related parties \| $										811		1,340	289
Stock option expense, Unamortized \| $										4,489		4,263	409
Stock option expense, Unamortized, Related parties \| $										$ 3,717		$ 3,664	$ 318
Options Outstanding										5,008,984		2,859,184	281,834
Options Outstanding, intrinsic value \| $										$ 0		$ 37	$ 0
Common Stock [Member]
Common shares issued for settlement of debt \| $													$ 11,000
Common stock shares issued during period													7,373,000
Common shares issued for cash (in shares)													1,564,188,000
Common shares issued for cash \| $													$ 1,978,000
Common stock, shares issued												19,535,116
Expenses payable \| $										$ 6,579
Common stock , shares issued for exercise of warrants										8,021,525
Proceeds from exercise of warrants \| $										$ 6,016
Offering costs \| $										$ 96			$ 1,923
Common stock, shares issued during period										1,393,591
Net proceeds \| $										$ 1,524
Average price \| $ / shares										$ 1.20
Commission fee \| $										$ 51
Gross sales price per share of common stock percentage										3.00%			2.00%
Number of issuance of common shares													1,644,221,000
Common shares issued for acquisition of license (in shares)													61,297,000
Common shares issued for settlement of debt (in shares)													11,363,000
Restricted Stock Awards [Member]
Stock-based compensation expense \| $										$ 0	$ 14	$ 34	$ 42
Director [Member]
Common shares issued for cash \| $													$ 55,000
Reversed expense \| $										$ 2
Number of cancelled common shares													6,250,000
Represents as a equity incentive plan. \| Director [Member]
Expiration date under plan					Dec. 06, 2029
Number of shares granted during period					10,000,000	22,250,000
Exercise price \| $ / shares					$ 2.65
Stock option value \| $					$ 24
Information about equity incentive plan. \| Director [Member]
Expiration date under plan					Dec. 06, 2029
Number of shares granted during period					40,000,000
Exercise price \| $ / shares					$ 2.65
Stock option value \| $					$ 98
2018 Equity Incentive Plan
Common stock reserved for future issuance										2,000,000				2,115,051	3,674,097
Common stock, shares available to be issued										2,213,851				4,586,554
Common stock, shares issuable										7,222,835
2018 Equity Incentive Plan \| Subsequent Event [Member]
Shares returned to option pool	257,652
Common stock reserved for future issuance														2,115,051
Common stock, shares available to be issued														4,586,554
2018 Equity Incentive Plan \| Employees Directors And Consultants [Member]
Options granted										794,800
Options granted exercise price \| $ / shares										$ 0.63
Options granted term										ten (10) years
Options issued to non-employees vesting percentage										33.00%
Options issued to non-employees vesting period										24-month
Options issued to employees vesting period										36-month
2018 Equity Incentive Plan \| Principal Executive Officer [Member]
Options granted										1,355,000
Options granted exercise price \| $ / shares										$ 0.63
Options granted term										ten (10) years
Options issued to non-employees vesting percentage										25.00%
Options issued to non-employees vesting period										24-month
Options issued to employees vesting period										36-month
Options granted in fiscal year 2021 [Member]
Options issued to non-employees vesting percentage		25.00%	50.00%
Exercise price \| $ / shares		$ 1.52	$ 2.66				$ 1.00	$ 0.6035
Options granted to purchase shares of common stock		575,100	834,500				70,000
Options Granted								120,000
Options grant description								The Company anticipates the compensation to be $15 to $20 per year for the first year and $20 to $30 for the second year and thereafter, subject to formal approval by the Board.
Options granted in fiscal year 2021 [Member] \| Options 2 [Member]
Options issued to non-employees vesting percentage			25.00%
Exercise price \| $ / shares			$ 2.66
Options granted to purchase shares of common stock			420,000
Options granted in fiscal year 2021 [Member] \| Options 1 [Member]
Options issued to non-employees vesting percentage			50.00%
Exercise price \| $ / shares		$ 1.52	$ 2.66
Options granted to purchase shares of common stock		30,000	705,500
Options forfeited in fiscal year 2021 [Member]
Unvested stock options							177,750
Vested stock options							23,750
Underwriting Agreement [Member] \| Ladenburg Thalmann [Member] \| Over-Allotment Option [Member]
Number of warrants sold																	1,320,000,000	1,320,000,000
January 1, 2020 \| Represents as a equity incentive plan.
Expiration date under plan										Dec. 13, 2029
Number of shares granted during period										24,000
Exercise price \| $ / shares																			$ 2.12
Stock option value \| $										$ 68
Common shares issued for cash (in shares)													1,518,354,000